Related Experiment Video
Updated: Jan 30, 2026

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus
Published on: May 13, 2021
Construction of Oncolytic Herpes Simplex Virus with Therapeutic Genes of Interest
Andranik Kahramanian1, Toshihiko Kuroda1, Hiroaki Wakimoto2
1Department of Neurosurgery, Brain Tumor Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Abstract:
Herpes simplex virus (HSV) is one of the most extensively studied oncolytic virus platforms. The recent FDA approval of talimogene laherparepvec (T-VEC) has been accelerating translational research of oncolytic HSV (oHSV) as a promising therapeutic for refractory cancers such as glioblastoma, the deadliest primary malignancy in the brain. The large genome size of HSV readily allows arming of oHSV by incorporating therapeutic transgenes within the virus, as exemplified by T-VEC carrying GM-CSF, thereby enhancing the anticancer activity of oHSV. Here we describe a bacterial artificial chromosome-based method for construction of an oHSV expressing a transgene, which we routinely use in the laboratory to create a number of different recombinant oHSV bearing either therapeutic or reporter genes.
Insights
Oncolytic herpes simplex virus (oHSV) shows promise for treating cancers like glioblastoma. Researchers developed a method using bacterial artificial chromosomes to engineer oHSV with therapeutic genes, enhancing its anti-cancer potential.
Area of Science:
- Oncolytic virotherapy
- Cancer gene therapy
- Molecular virology
Background:
- Herpes simplex virus (HSV) is a well-researched platform for oncolytic virotherapy.
- The FDA approval of talimogene laherparepvec (T-VEC) has spurred interest in oncolytic HSV (oHSV) for treating difficult cancers, including glioblastoma.
- HSV's large genome facilitates the incorporation of therapeutic transgenes to boost anticancer activity.
Purpose of the Study:
- To describe a bacterial artificial chromosome (BAC)-based method for constructing oHSV.
- To demonstrate the creation of recombinant oHSV vectors expressing transgenes for therapeutic or reporter purposes.
Main Methods:
- Utilized a bacterial artificial chromosome (BAC) system for oHSV genome manipulation.
- Engineered oHSV to express specific transgenes by incorporating them into the viral genome.
- Routinely applied this method in the laboratory for oHSV construction.
Main Results:
- Successfully developed and implemented a BAC-based method for oHSV construction.
- Created multiple recombinant oHSV vectors carrying different therapeutic or reporter genes.
- Established a reproducible laboratory workflow for oHSV engineering.
Conclusions:
- The described BAC-based method provides a robust platform for generating engineered oHSV.
- This approach facilitates the development of novel oHSV therapies with enhanced anticancer efficacy.
- The method is adaptable for creating oHSV expressing various transgenes for diverse research and therapeutic applications.
Related Concept Videos
What are Viruses?
Gene Therapy
Therapeutic Index
Therapeutic Communication
Verbal communication depends on language or a prescribed way of using words so that people can share information effectively. The critical aspects of verbal...
Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Microorganisms in Medicine and Therapeutics

